SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Senetek (SNTK)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jh20067/1/2008 10:23:23 AM
   of 101
 
Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM)
Tuesday July 1, 9:30 am ET

NAPA, California, July 1 /PRNewswire/ -- Senetek PLC (OTC Bulletin Board: SNKTY - News), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that effective with the termination of its marketing agreement with Triax Aesthetics LLC for Pyratine-6(TM), all promotion, sales and distribution of Pyratine-6(TM) would be controlled and managed directly by the Company.
ADVERTISEMENT


Phil Rose, Senetek's Chief Operating Officer stated, "We are building an infrastructure that has the expertise to establish Pyratine-6(TM) as the leading anti-aging product in the physician channel. The clinical data supporting Pyratine-6(TM) provides a clear and differential advantage over the competition. We are moving forward quickly and strategically without any looking back. We have the foundation and experience for success."

Bill O'Kelly, Senetek's Chief Financial Officer stated, "We are finalizing the operating and financial plan associated with the Company's promotion, sales and distribution of Pyratine-6(TM) and we will communicate appropriate aspects of the plan to our shareholders when
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext